ArticleESC heart failure2024
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.
Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03842163 (PREVALENCE AND CHARACTERISTICS OF TRANSTHYRETIN AMYLOIDOSIS IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY OF UNKNOWN ETIOLOGY TTRACK), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence and characteristics of transthyretin amyloidosis in patients with left ventricular hypertrophy of unknown etiology ttrack
Who cites it
15 citing papers in PubMed.
- Wild-type transthyretin cardiac amyloidosis: the journey to diagnosis in the Czech Republic : The research project of the Czech Society of Cardiology.Orphanet journal of rare diseases · 2026Article
- Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study.ESC heart failure · 2026Article
- Closing the diagnostic gap in transthyretin cardiac amyloidosis: red flags, modern imaging, and emerging therapies.Frontiers in cardiovascular medicine · 2026Review
- Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study.American journal of cardiovascular disease · 2026Article
- Comparative transcriptome analysis provides new insights into the molecular mechanism of blunt snout bream (Megalobrama amblycephala) heart in response to hypoxic stress.Fish physiology and biochemistry · 2025Article
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.ESC heart failure · 2025Article
- Cellular and Molecular Mechanisms of Heart Failure and Sudden Cardiac Death in Hypertrophic Cardiomyopathy and Methods Used for Their Pathogenetic Correction.Biomedicines · 2025Review
- Transthyretin Amyloidosis-One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19.International journal of molecular sciences · 2025Article
- Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure.JAMA cardiology · 2025Article
- Management of Cardiac Amyloidosis With Concomitant Left Ventricular Outflow Tract Obstruction.JACC. Case reports · 2025Article
- Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy.ESC heart failure · 2025Article
- Variant cardiac transthyretin amyloidosis presenting as hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: a case report.European heart journal. Case reports · 2025Article
- Multiple Red Flags of Cardiac Amyloidosis in a Single Patient: Clinical Manifestations of an Underdiagnosed Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.ESC heart failure · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsRecognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics. We examined the prevalence and characteristics of transthyretin amyloid cardiomyopathy in older patients with hypertrophic cardiomyopathy of unascertained aetiology. METHODS AND
resultsTTRACK was a multicentre, non-interventional, cross-sectional epidemiologic study funded by Pfizer and conducted in 20 hospitals and medical centres in 11 countries (NCT03842163). Eligible patients were aged ≥50 years, had hypertrophic cardiomyopathy (maximal end-diastolic left ventricular wall thickness ≥15 mm on echocardiogram) without an identified genetic or alternative origin at study enrolment, and underwent
conclusionsIn the TTRACK study, almost one in five patients ≥50 years of age with hypertrophic cardiomyopathy had transthyretin amyloid cardiomyopathy. Greater awareness of the frequency and characteristics of transthyretin amyloid cardiomyopathy in older patients with hypertrophic cardiomyopathy are needed to help improve early detection of this debilitating but treatable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.